Table 2.
Multivariate analysis of S100A8/A9, LDH, and M stage on progression-free survival in the pembrolizumab-treated patients (pembrolizumab set 2)
| Patients | ||||||
|---|---|---|---|---|---|---|
| No. | % | % Prog. |
HR | 95% CI | p value | |
| S100A8/A9 | ||||||
| ≤ 5.5 mg/l | 39 | 88.6 | 48.7 | 1 | ||
| > 5.5 mg/l | 5 | 11.4 | 100.0 | 10.1 | 2.72–37.6 | .00055 |
| LDH | ||||||
| ≤ 2,5xULN | 40 | 90.9 | 52.5 | 1 | ||
| > 2,5xULN | 4 | 9.1 | 75.0 | 2.19 | 0.48–10.1 | .31 |
| M stage | ||||||
| M0/M1a/b | 14 | 31.8 | 57.1 | 1 | ||
| M1c | 30 | 68.2 | 53.3 | 0.68 | 0.22–2.08 | .50 |
NOTE. Multivariate survival analysis included 44 patients of the pembrolizumab set 2. The model was adjusted for age and sex
Abbreviations: CI confidence interval, HR hazard ratio, ICI immune checkpoint inhibitor, LDH lactate dehydrogenase, Prog. progression, ULN upper limit of normal